{
    "data": [
        {
            "title": "Should Northern Trust's New AI Hedging and CLO Services Strategy Prompt Action From NTRS Investors?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent weeks, Northern Trust expanded its CLO middle-office services on the Omnium platform and broadened its dynamic currency hedging framework by adding Berenberg‚Äôs AI-based models, giving institutional clients more sophisticated compliance, waterfall calculation, and currency risk management options across major global markets.</li> <li>Together, these moves highlight Northern Trust‚Äôs emphasis on technology-enabled, fee-based services that aim to enhance operational efficiency and risk management for asset owners and asset managers.</li> <li>Next, we‚Äôll explore how the addition of AI-driven currency hedging and enhanced CLO servicing could reshape Northern Trust‚Äôs investment narrative.</li> </ul><p>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Northern Trust Investment Narrative Recap</h2><p>Northern Trust‚Äôs appeal rests on its ability to compound fee-based income while keeping costs and risks under control, even as revenue growth trails the wider market. The latest CLO and AI currency hedging upgrades support that services-led story, but do not fundamentally change the near-term picture where slower expected earnings growth and pressure on margins remain key issues to watch.</p> <p>Among recent announcements, the expanded CLO middle-office services on the Omnium platform look most relevant, because they align with Northern Trust‚Äôs push to deepen relationships with complex asset managers. If these offerings help defend fee pools and support operating efficiency, they may partially offset the risk that modest revenue growth, rising expenses, or competitive pressure leaves returns on equity and profit growth below investor expectations.</p> <p>Yet behind these technology wins, investors should also be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-ntrs/northern-trust/qqtlltpw-fee-headwinds-and-market-shifts-will-shape-margins-in-coming-quarters\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Northern Trust (it's free!)</a></p><p>Northern Trust's narrative projects $8.2 billion revenue and $1.4 billion earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-ntrs/northern-trust/qqtlltpw-fee-headwinds-and-market-shifts-will-shape-margins-in-coming-quarters\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Northern Trust's forecasts yield a $157.11 fair value</a>, a 6% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NTRS 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a87509c2-2599-4108-bf2b-e61b0678e533/chart/quote-price\" width=\"746\"/></a><figcaption>NTRS 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span from about US$156 to over US$254,541 per share, showing how far opinions can spread. Set against this, the core catalyst of technology-enabled, fee-based services and the risk of slower earnings growth than the wider market give you important context for assessing which narratives about Northern Trust‚Äôs future you find most convincing.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Northern Trust</a> - why the stock might be worth just $156.54!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Northern Trust research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Northern Trust research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Northern Trust's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Northern Trust might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 04:26:06",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust/news/should-northern-trusts-new-ai-hedging-and-clo-services-strat",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "What Viking Holdings (VIK)'s New 2027 U.S. River Cruise Itineraries Mean For Shareholders",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Viking¬Æ announced that bookings are open for several new 2027 itineraries on the Mississippi and Ohio rivers, including 8-, 15-, and 22-day destination-focused cruises between New Orleans, Memphis, Louisville, St. Louis, and St. Paul.</li> <li>By deepening its focus on culturally rich American river routes, spanning Civil War sites, musical heritage, and regional cuisine, Viking is broadening its appeal to experience-driven travelers seeking immersive itineraries.</li> <li>We‚Äôll now examine how Viking‚Äôs expansion of Mississippi and Ohio river sailings could influence its investment narrative built around heritage experiences.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Viking Holdings Investment Narrative Recap</h2><p>To own Viking, you need to believe in its ability to turn an expanding portfolio of culturally rich itineraries into durable demand and healthy margins, while managing high debt and cost pressures. The new Mississippi and Ohio river sailings strengthen the near term catalyst of strong advance bookings by adding more heritage-led product in the key U.S. market, but they do not materially change the biggest current risk around elevated leverage and exposure to older, premium travelers.</p> <p>Among recent announcements, the multi year marketing partnership with the PGA TOUR through 2030 is especially relevant. Together with the new Mississippi and Ohio cruises, it reinforces Viking‚Äôs push into the U.S., supporting the catalyst of capacity expansion into new geographies and potentially helping sustain strong booking trends that analysts are watching ahead of the upcoming Q4 2025 results on March 3, 2026.</p> <p>Yet beneath the appeal of Viking‚Äôs new itineraries, investors should also be aware of how its high debt and older customer base could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-vik/viking-holdings/ty502cz7-global-expansion-will-unlock-premium-travel-experiences-7q8c\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Viking Holdings (it's free!)</a></p><p>Viking Holdings' narrative projects $8.5 billion revenue and $2.0 billion earnings by 2028. This requires 13.6% yearly revenue growth and about a $1.3 billion earnings increase from $694.2 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-vik/viking-holdings/ty502cz7-global-expansion-will-unlock-premium-travel-experiences-7q8c\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Viking Holdings' forecasts yield a $74.06 fair value</a>, a 7% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"VIK 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bd8946f-41e1-46d9-8eb2-91286843a6af/chart/quote-price\" width=\"746\"/></a><figcaption>VIK 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were already expecting Viking to reach about US$8.9 billion in revenue and US$2.2 billion in earnings by 2028, which is a far more upbeat view than the baseline narrative and assumes that advantages like prime river access translate into much stronger growth, so you should weigh this against the new Mississippi and Ohio routes and consider how both optimistic and more cautious theses might evolve from here.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Viking Holdings</a> - why the stock might be worth less than half the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Viking Holdings research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Viking Holdings research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Holdings' overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>The latest GPUs need a type of rare earth metal called Terbium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">29 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:26:06",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings/news/what-viking-holdings-viks-new-2027-us-river-cruise-itinerari",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "How Investors May Respond To Sunrun (RUN) Profit Swing and Surging Home Storage Adoption",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Sunrun Inc. has reported its fourth-quarter and full-year 2025 results, with sales reaching US$466.49¬†million for the quarter and US$1.82¬†billion for the year, revenue of US$1.16¬†billion for the quarter and US$2.96¬†billion for the year, and a swing from a multi‚Äëbillion‚Äëdollar net loss in 2024 to net income of US$103.57¬†million for the quarter and US$449.95¬†million for 2025.</li> <li>Beyond the earnings beat, Sunrun‚Äôs growing battery footprint, now more than 217,000 residential systems and a 71% storage attachment rate, underpins its expanding role in grid services, highlighted by a successful distributed power plant season with PG&amp;E that achieved nearly 99% dispatch accuracy across over 1,200 hours.</li> <li>We‚Äôll now examine how Sunrun‚Äôs sharp turnaround to profitability and rising storage attachment rates might reshape its existing investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Sunrun Investment Narrative Recap</h2><p>To own Sunrun, you need to believe residential solar plus storage can remain attractive even as tax credits phase out and financing stays complex. The latest earnings beat and return to profitability strengthen the case that scale and higher storage attachment can support margins, but the biggest near term swing factor is still access to affordable capital, while long term policy uncertainty around incentives remains a key overhang. This quarter‚Äôs results do not remove those risks, but they do improve Sunrun‚Äôs financial footing.</p> <p>The most relevant recent development is Sunrun‚Äôs completion of the PG&amp;E Local PeakShift Power season, where over 1,000 customer systems delivered nearly 1,200 hours of highly accurate dispatch. Paired with storage attachment rates reaching 71% by year end 2025, this grid services performance gives more substance to the idea that batteries and virtual power plants could become a meaningful earnings driver, potentially offsetting some pressure from expiring tax credits and higher financing costs over time.</p> <p>Yet while the profit rebound is encouraging, investors should also be aware that concentrated policy risk around solar tax credits could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Sunrun (it's free!)</a></p><p>Sunrun's narrative projects $2.9 billion revenue and $465.4 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Sunrun's forecasts yield a $22.74 fair value</a>, a 11% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"RUN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9fa2a4c7-de78-47ca-906e-c5edae8a6116/chart/quote-price\" width=\"746\"/></a><figcaption>RUN 1-Year Stock Price Chart</figcaption></figure> <p>Before this surprise profit, the most bearish analysts assumed almost flat revenue growth near US$2.1 billion and no profitability, so their far more cautious view of Sunrun‚Äôs financing and policy risks may shift meaningfully as investors reassess those assumptions.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Sunrun</a> - why the stock might be worth as much as 32% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Sunrun research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Sunrun research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sunrun's overall financial health at a glance.</li></ul><h2>No Opportunity In Sunrun?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:26:06",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun/news/how-investors-may-respond-to-sunrun-run-profit-swing-and-sur",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Amneal Pharmaceuticals recently issued 2026 earnings guidance, projecting net revenue between US$3.05¬†billion and US$3.15¬†billion, alongside heightened attention around its latest quarterly earnings release.</li> <li>This new guidance gives investors a clearer view of management‚Äôs expectations for the scale of Amneal‚Äôs business as it expands across generics, injectables, biosimilars, and specialty products.</li> <li>We‚Äôll now examine how Amneal‚Äôs US$3.05‚Äì3.15¬†billion 2026 revenue outlook may influence the existing investment narrative built around diversification.</li> </ul><p>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Amneal Pharmaceuticals Investment Narrative Recap</h2><p>To own Amneal, you need to believe its push across generics, injectables, biosimilars, and specialty products can offset pricing pressure and legal costs while supporting sustainable scale. The new 2026 revenue guidance of US$3.05‚Äì3.15 billion reinforces that diversification story but does not materially change the near term focus on execution in higher margin categories or the key risk around ongoing pricing and regulatory pressures.</p> <p>The most relevant recent announcement here is the nationwide opioids settlement, which commits Amneal to up to US$88.5 million in cash payments and up to US$177.4 million in naloxone product. That settlement helps clarify a major legal overhang just as management is asking investors to weigh its revenue outlook and pipeline against elevated leverage and the cost of maintaining compliance and quality across a broad portfolio.</p> <p>Yet behind this clearer revenue outlook and legal visibility, investors should still be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Amneal Pharmaceuticals (it's free!)</a></p><p>Amneal Pharmaceuticals‚Äô narrative projects $3.5 billion revenue and $207.9 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Amneal Pharmaceuticals' forecasts yield a $15.20 fair value</a>, a 5% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"AMRX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/quote-price\" width=\"746\"/></a><figcaption>AMRX 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span roughly US$11.94 to about US$70 per share, showing how far apart individual views on Amneal‚Äôs potential can be. Against that backdrop, Amneal‚Äôs new 2026 revenue guidance invites you to weigh its diversification catalyst alongside ongoing pricing and regulatory risks that could influence how those projections translate into business performance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Amneal Pharmaceuticals</a> - why the stock might be worth over 4x more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Amneal Pharmaceuticals research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 stocks that are working to make quantum computing a reality</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:26:06",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/the-bull-case-for-amneal-pharmaceuticals-amrx-could-change-f-3",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is National Energy Services Reunited (NESR) Share Surge Justified By Recent Valuation Signals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>This article is designed to help you assess whether National Energy Services Reunited still represents good value after its recent share price run, or whether the excitement has moved ahead of the company‚Äôs fundamentals.</li> <li>The stock last closed at US$25.14, with returns of 3.9% over 7 days, 26.0% over 30 days, 59.2% year to date and 207.7% over the past year, as well as 278.6% over 3 years and 95.0% over 5 years.</li> <li>These moves have put the company on more investors' radar, and they have been looking more closely at how its current price lines up with its underlying worth. That is where a structured valuation review comes in, using multiple methods to see whether the recent share price action still matches the fundamentals.</li> <li>On our Simply Wall St checks, National Energy Services Reunited scores 2 out of 6 on valuation, which you can see in detail in our <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation scorecard</a>. Next we will walk through the different ways investors commonly assess value, before finishing with a more complete way to think about valuation as a whole.</li> </ul> <p>National Energy Services Reunited scores just 2/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: National Energy Services Reunited Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes the cash that a company is expected to generate in the future and discounts it back to today to estimate what the entire business could be worth now.</p> <p>For National Energy Services Reunited, the latest twelve month Free Cash Flow is about $153.0 million. The model used here is a 2 Stage Free Cash Flow to Equity approach, which first applies analyst forecasts and then extends those cash flows further out using additional assumptions by Simply Wall St.</p> <p>The projections used in the model include Free Cash Flow of $154.6 million in 2026 and $219.0 million in 2028, with further years out to 2035 based on extrapolated estimates, all in $. When these projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $58.38 per share.</p> <p>Compared with the recent share price of $25.14, this DCF estimate suggests a difference of around 56.9% between the modelled intrinsic value and the current market price.</p> <p><strong>Result: UNDERVALUED (based on this DCF model)</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests National Energy Services Reunited is undervalued by 56.9%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NESR Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>NESR Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for National Energy Services Reunited.</a></p> <h2>Approach 2: National Energy Services Reunited Price vs Earnings</h2> <p>For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. This makes it a useful cross check alongside a DCF model. What counts as a ‚Äúnormal‚Äù P/E depends on what the market expects for future earnings growth and how risky those earnings are, with higher expected growth or lower perceived risk usually supporting a higher multiple.</p> <p>National Energy Services Reunited currently trades on a P/E of about 49.6x. That sits above both the Energy Services industry average of roughly 26.6x and the peer group average of about 32.7x. This suggests the market is applying a richer multiple than these broad comparison points.</p> <p>Simply Wall St‚Äôs Fair Ratio for the stock is 25.9x. This is a proprietary estimate of what the P/E might be based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it ties the multiple to these fundamentals, the Fair Ratio can offer a more tailored reference point than a simple peer or industry comparison.</p> <p>When set against the current P/E of 49.6x, the Fair Ratio of 25.9x points to the shares trading on a higher multiple than this framework would suggest.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your National Energy Services Reunited Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you set out your story for National Energy Services Reunited, link that story to a forecast for revenue, earnings and margins, and then see the Fair Value that falls out of those assumptions so you can compare it with the current share price.</p> <p>Instead of only relying on a single P/E or DCF number, a Narrative combines your view of the business with a live model. It updates automatically when new earnings or news arrive, and is available on the Community page where millions of investors share their own versions.</p> <p>For example, one National Energy Services Reunited Narrative might align with the bullish analyst fair value of US$30.00, built around confidence in hydraulic fracturing capacity and MENA contracts. Another could sit nearer the cautious US$10.00 view that focuses on regional concentration and energy transition risks. Seeing those side by side can help you decide whether the current US$25.14 price is above or below the story you find most convincing.</p> <p>For National Energy Services Reunited, here are previews of two leading National Energy Services Reunited narratives that may help frame the discussion:</p> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/lj4o0x5w-rising-mena-demand-will-boost-oilfield-service-expansion-mfij?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ National Energy Services Reunited Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$30.00 per share</p> <p>Current price vs this fair value: about 16.1% below the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 19.65% a year</p> <ul> <li>Supports a higher fair value case built around hydraulic fracturing scale in Saudi Arabia, contract visibility across MENA and higher profit margins tied to technology and efficiency gains.</li> <li>Assumes National Energy Services Reunited can sustain robust revenue growth and margin expansion, with future earnings and P/E considered consistent with a US$30.00 anchor valuation.</li> <li>Notes meaningful risks from oilfield concentration, regional exposure and capital intensity, so the optimistic outcome still depends on execution and stable operating conditions.</li> </ul> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/1sh65zqm-revenue-recovery-and-sector-rebound-will-drive-long-term-shareholder-returns?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª National Energy Services Reunited Bear Case</strong></a></p> <p>Fair value in this more cautious narrative: US$22.14 per share</p> <p>Current price vs this fair value: about 13.5% above the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 18.93% a year</p> <ul> <li>Frames the story around solid MENA contracts and Jafurah exposure, but anchors fair value closer to US$22.14, even with updated analyst targets around US$30.</li> <li>Builds in steady revenue growth and margin improvement, while assuming a more modest future P/E multiple compared with the bullish view.</li> <li>Highlights contract concentration, capital demands, working capital strain and long term energy transition as key risks that could keep the share price nearer this fair value.</li> </ul> <p>Viewed together, these narratives provide two different sets of assumptions for National Energy Services Reunited that can be compared with the current US$25.14 share price.</p> <p>Do you think there's more to the story for National Energy Services Reunited? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqCM/NESR\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if National Energy Services Reunited might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 04:26:05",
            "link": "https://simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/news/is-national-energy-services-reunited-nesr-share-surge-justif",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is It Too Late To Consider CACI International (CACI) After Its Strong Multi‚ÄëYear Rally?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Wondering if CACI International at around US$597 per share still offers value, or if most of the opportunity has already been reflected in the price?</li> <li>The stock has had a mixed recent run, with a 1% gain over the last 7 days, a 7.2% decline over 30 days, an 11.1% return year to date, and a 77.9% return over the past year, following a 102.4% return over 3 years and 175.8% over 5 years.</li> <li>These moves have kept CACI on many investors' watchlists, as they reassess what is already priced in and what might still be up for debate. While there has not been a single headline recently that fully explains the share price path, ongoing interest in defense and government services providers has kept sentiment around CACI in focus.</li> <li>On our valuation checklist, CACI International scores 5 out of 6 for being undervalued, giving it a value score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nyse-caci/caci-international/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">5</a>. Next, we will look at how different valuation methods stack up for the stock, and then finish with a way to judge value that goes beyond any single model.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_performance_contextual\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nyse-caci/caci-international/past\" rel=\"noopener noreferrer\" target=\"_blank\">CACI International delivered 77.9% returns over the last year. See how this stacks up to the rest of the Professional Services industry.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: CACI International Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes the cash CACI International is expected to generate in the future, then discounts those projections back to today to estimate what the business could be worth in total.</p> <p>For CACI, the latest twelve month Free Cash Flow is about $637.3 million. Analysts have provided forecasts that feed into a 2 Stage Free Cash Flow to Equity model, with Simply Wall St extending the projections further out. Within that framework, projected Free Cash Flow for 2035 is $1,014.98 million, based on a mix of analyst inputs and extrapolated estimates.</p> <p>When all those forecast cash flows are discounted back to today, the model arrives at an estimated intrinsic value of around $812.41 per share. Versus a recent share price near $597, this suggests the stock is trading at roughly a 26.5% discount to that DCF estimate. On this cash flow based approach, the model result indicates that CACI may be undervalued.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests CACI International is undervalued by 26.5%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nyse-caci/caci-international/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CACI Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1429557d-de3e-47fa-b954-56434f5f9dd9/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>CACI Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nyse-caci/caci-international/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CACI International.</a></p> <h2>Approach 2: CACI International Price vs Earnings</h2> <p>For profitable companies, the P/E ratio is a useful shortcut because it ties what you are paying directly to the earnings the business is already generating. It reflects both what the market thinks of those earnings today and how it is weighing the risks around them.</p> <p>Higher growth expectations and lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to pull a ‚Äúnormal‚Äù or ‚Äúfair‚Äù P/E lower. CACI International currently trades on a P/E of about 25.4x. That sits above the Professional Services industry average of roughly 20.6x, but below the peer group average of around 28.0x.</p> <p>Simply Wall St‚Äôs Fair Ratio for CACI is 27.2x, which is its proprietary estimate of what a reasonable P/E might be given the company‚Äôs earnings characteristics, industry, profit margins, market cap and risk profile. This can be more tailored than a simple peer or industry comparison, because it adjusts for factors that can differ meaningfully between companies. With the current P/E of 25.4x sitting modestly below the Fair Ratio of 27.2x, the multiple suggests the stock may be undervalued on this basis.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nyse-caci/caci-international/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CACI P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1429557d-de3e-47fa-b954-56434f5f9dd9/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:CACI P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your CACI International Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. Simply Wall St makes these available on the Community page so you can connect CACI International‚Äôs story to your own numbers by linking your assumptions about future revenue, earnings, margins and fair value to a clear forecast. You can compare that fair value to today‚Äôs price to think about when you might buy or sell, and see those views update automatically as new earnings or news arrive. Whether you lean closer to a cautious view that anchors on a fair value around US$670 or a more optimistic view closer to US$751, you can explore these perspectives within an easy, story first framework that is already being used by millions of investors.</p> <p>Do you think there's more to the story for CACI International? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/CACI\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/commercial-services/nyse-caci/caci-international\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CACI 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1429557d-de3e-47fa-b954-56434f5f9dd9/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:CACI 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:20:56",
            "link": "https://simplywall.st/stocks/us/commercial-services/nyse-caci/caci-international/news/is-it-too-late-to-consider-caci-international-caci-after-its",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SSR Mining (TSX:SSRM) Is Up 10.2% After Earnings Rebound And $300M Buyback Plan - Has The Bull Case Changed?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>SSR Mining Inc. recently reported its fourth-quarter and full-year 2025 results, showing higher annual gold equivalent production of 447,207 ounces, a swing from a prior-year net loss to US$395.75 million in net income on US$1.63 billion in sales, and announced a US$300 million share repurchase program.</li> <li>The combination of stronger profitability, improved production trends and management‚Äôs decision to allocate US$300 million to buybacks highlights a focus on capital returns alongside operating growth.</li> <li>Next, we‚Äôll examine how the sharp earnings rebound and new US$300 million buyback shape SSR Mining‚Äôs existing investment narrative and outlook.</li> </ul><p>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>SSR Mining Investment Narrative Recap</h2><p>To own SSR Mining today, you need to be comfortable tying your fortunes to a multi-jurisdiction precious metals producer that is profitable but still wrestling with √á√∂pler‚Äôs uncertainty and elevated reclamation costs. The sharp earnings rebound and higher 2025 output help underpin confidence in near term cash generation, yet the key swing factor remains timing, cost, and regulatory clarity around √á√∂pler, which this latest update does not meaningfully resolve.</p> <p>The newly announced US$300 million share repurchase program is the most relevant piece of news here, because it sits alongside 2026 production guidance of 450,000 to 535,000 gold equivalent ounces and relatively high AISC, especially once √á√∂pler care and maintenance is included. For investors, that pairing puts a brighter spotlight on the trade off between returning cash today and preserving balance sheet flexibility if √á√∂pler remediation costs or regulatory delays turn out to be more onerous than currently expected.</p> <p>Yet, even with higher earnings and buybacks, investors should be aware that √á√∂pler‚Äôs unresolved regulatory path and rising reclamation estimates could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/ca/materials/tsx-ssrm/ssr-mining-shares/fnivcwfn-ssrm-higher-gold-price-forecasts-will-spark-continued-share-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on SSR Mining (it's free!)</a></p><p>SSR Mining's narrative projects $2.3 billion revenue and $792.9 million earnings by 2028. This requires 20.1% yearly revenue growth and a $627.9 million earnings increase from $165.0 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/ca/materials/tsx-ssrm/ssr-mining-shares/fnivcwfn-ssrm-higher-gold-price-forecasts-will-spark-continued-share-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how SSR Mining's forecasts yield a CA$38.85 fair value</a>, a 12% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/ca/materials/tsx-ssrm/ssr-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSX:SSRM 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9ec00909-12d0-484a-aba9-ca830c35ae80/chart/quote-price\" width=\"746\"/></a><figcaption>TSX:SSRM 1-Year Stock Price Chart</figcaption></figure> <p>Before this update, the most optimistic analysts were penciling in roughly US$2.6 billion of revenue and US$745.7 million of earnings by 2028, yet the latest results and √á√∂pler risk remind you that such bullish views sit at one end of a wide range of opinions that could shift as new information comes through.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/ca/materials/tsx-ssrm/ssr-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 6 other fair value estimates on SSR Mining</a> - why the stock might be worth over 2x more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your SSR Mining research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/ca/materials/tsx-ssrm/ssr-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/ca/materials/tsx-ssrm/ssr-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free SSR Mining research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SSR Mining's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:</p><ul><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/ca\" rel=\"noopener noreferrer\" target=\"_blank\">6 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Outshine the giants: these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 early-stage AI stocks could fund your retirement</a>.</li><li>The latest GPUs need a type of rare earth metal called Neodymium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">32 companies in the world exploring or producing it</a>. Find the list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:20:56",
            "link": "https://simplywall.st/stocks/ca/materials/tsx-ssrm/ssr-mining-shares/news/ssr-mining-tsxssrm-is-up-102-after-earnings-rebound-and-300m",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Range Resources Links Higher Dividend And Decade Long Gas Contract For Visibility",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Range Resources (NYSE:RRC) has approved an 11% increase to its dividend, reinforcing its focus on shareholder returns.</li> <li>The company has also entered into a 10 year natural gas supply agreement with a Midwest power plant, securing long term demand for its production.</li> </ul> <p>For investors watching NYSE:RRC, these two moves connect income and business stability. The stock trades at $39.09, with a value score of 3 and multi year returns that include 47.7% over 3 years and 292.0% over 5 years, which outlines how the market has already been pricing the company. The recent 30 day return of 9.3% and year to date gain of 10.7% show that the shares have had some momentum into this news.</p> <p>The higher dividend and 10 year supply contract both indicate management‚Äôs view on cash generation and the durability of demand for its gas. As you assess NYSE:RRC, these developments may matter if you care about visibility on future cash flows and income potential, especially compared with other energy names that do not combine dividend changes with long term offtake agreements.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-rrc/range-resources/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Range Resources</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/RRC\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Range Resources.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-rrc/range-resources/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:RRC Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/8e3e6a4c-68df-4d1f-be90-ac61c11bf1ee/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:RRC Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_dividend\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-rrc/range-resources/dividend\" rel=\"noopener noreferrer\" target=\"_blank\">Is Range Resources's dividend sustainable? Check out what every dividend investor needs to know in our dividend analysis.</a></p> <p>The 11% increase in Range Resources‚Äô quarterly dividend to US$0.10 per share, or US$0.40 annualized, comes right after a year where the company reported higher revenue and net income for 2025 and generated over US$650m in free cash flow. For you as a shareholder, the timing matters because management is pairing the dividend move with a larger buyback authorization and a 10 year gas sales contract to a Midwest power plant, which together point to confidence in future cash generation and demand visibility. The contract ties a slice of production to a single large customer, which can smooth volumes compared with fully spot exposure.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Range Resources Narrative</h3> <ul> <li>The long term power-plant contract supports the narrative that regional demand from power and data center loads can underpin Range Resources‚Äô Marcellus-focused gas strategy.</li> <li>The step up in shareholder returns, including the dividend increase and expanded repurchase program, could test the narrative if capital needs for drilling and processing expansions turn out higher than expected.</li> <li>The specific 10 year offtake agreement to a Midwest power plant, and its contract terms, are not fully captured in the broader narrative around LNG exports and data center demand.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/0cxwm1v1-rrc-medium-term-demand-from-lng-exports-and-datacenters-will-drive-upside\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Range Resources</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è A larger recurring cash dividend reduces flexibility if future drilling or processing costs rise faster than expected.</li> <li>‚ö†Ô∏è Concentration in Appalachia and reliance on power and LNG-linked demand leave Range Resources exposed if regional prices or regulatory conditions become less favorable.</li> <li>üéÅ A higher dividend combined with a US$1.5b buyback capacity signals that recent free cash flow levels have given the board confidence in returning capital.</li> <li>üéÅ The 10 year gas supply agreement offers long term volume visibility that many peers such as EQT and Chesapeake Energy may not have to the same contract-specific extent.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to watch how the new dividend compares with free cash flow over the next few quarters, especially as Range Resources spends US$650m to US$700m on its 2026 capital program. The key questions are whether the company keeps covering the dividend and buybacks from cash generated, how liquids stay above 30% of production as guided, and whether the Midwest contract meaningfully affects realized pricing. It is also worth tracking any changes in analyst views on the stock, given the recent cluster of Hold ratings and target tweaks, to see if this capital return move changes perceptions of risk and return.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Range Resources, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/RRC\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Range Resources</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:20:56",
            "link": "https://simplywall.st/stocks/us/energy/nyse-rrc/range-resources/news/range-resources-links-higher-dividend-and-decade-long-gas-co",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Carnival Millions Launch And Ship Redeployment Reshape Onboard Revenue Story",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Carnival Cruise Line, part of Carnival Corporation &amp; (NYSE:CCL), has launched \"Carnival Millions\", described as the cruise industry's first fleetwide interactive lottery across its North American and European ships.</li> <li>The company is also redeploying the Carnival Adventure ship from Australia to North America, citing regulatory uncertainty and cost pressures in the Australian market.</li> </ul> <p>Carnival Corporation &amp; (NYSE:CCL) is focusing on new onboard entertainment with Carnival Millions, a lottery style product that runs across its fleet in North America and Europe. For you as an investor, this highlights an emphasis on guest engagement and potential incremental revenue from non ticket spending at a time when cruise operators are refining their onboard offerings.</p> <p>At the same time, moving Carnival Adventure from Australia to North America shows how management is adjusting deployment in response to regulation and operating costs in different regions. For your watchlist, the combination of a new entertainment product and a shift in ship positioning provides additional data points on how CCL is positioning its brand and fleet in key cruise markets.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-ccl/carnival-corporation/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Carnival Corporation &amp;</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/CCL\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Carnival Corporation &amp;.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-ccl/carnival-corporation/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CCL Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/106688cf-a61b-411b-8be3-747df2075482/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:CCL Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_hidden_strengths\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-ccl/carnival-corporation\" rel=\"noopener noreferrer\" target=\"_blank\">4 things going right for Carnival Corporation &amp; that this headline doesn't cover.</a></p> <p>Carnival Millions points to a push to grow higher margin, non ticket revenue by turning the Carnival HUB app into more of a real time entertainment and spending platform. For you, that sits alongside price changes to gratuities and beverage packages as part of a broader focus on onboard yield. The linked lottery format could also help differentiate Carnival from large peers like Royal Caribbean and Norwegian Cruise Line, which are also vying to keep guests spending once on board.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Carnival Corporation &amp; Narrative</h3> <ul> <li>The rollout of a fleetwide interactive lottery supports the narrative around stronger guest experience and higher onboard spend, which has been highlighted as a driver of revenue and margin improvement.</li> <li>Shifting Carnival Adventure out of Australia in response to regulation and costs illustrates how regional pressures can affect capacity management, which the narrative treats as a key tool for maintaining pricing power.</li> <li>The use of app based, real time gaming and linked experiences across ships adds a digital engagement angle that is not fully reflected in the focus on private destinations and loyalty programs.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n                        <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/20trwq8f-ccl-record-bookings-and-improved-guidance-will-drive-upside-into-2026\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Carnival Corporation &amp;</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Greater reliance on gaming and lottery style products could attract regulatory scrutiny or reputational questions in some markets.</li> <li>‚ö†Ô∏è Redeploying a ship away from Australia signals that higher regional costs and regulatory changes can affect route economics and future capacity decisions.</li> <li>üéÅ A fleetwide lottery tied to the Carnival HUB app may support higher onboard spend per guest and deeper engagement during each sailing.</li> <li>üéÅ Fine tuning ship deployment toward North America could align capacity with routes where demand and cost structures may be more favorable.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to watch how quickly Carnival Millions is adopted across the fleet, how frequently guests participate, and whether management starts to call out lottery related revenue separately. On the deployment side, any further comments on Australian regulation, operating costs, or additional redeployments could signal how flexible Carnival is willing to be with its global footprint compared with peers. You can also track whether new entertainment formats and route shifts are mentioned in future guidance updates or earnings commentary as contributors to onboard yield and capacity plans.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Carnival Corporation &amp;, head to the\n                        <a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/CCL\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Carnival Corporation &amp;</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:20:56",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-ccl/carnival-corporation/news/carnival-millions-launch-and-ship-redeployment-reshape-onboa",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Metrovacesa (BME:MVC) Valuation Check After Strong Full Year Profit Rebound",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Metrovacesa earnings spark fresh interest in the stock</h2> <p>Metrovacesa (BME:MVC) has attracted fresh attention after reporting full year 2025 net income of ‚Ç¨56.86 million, compared with ‚Ç¨15.89 million a year earlier, alongside higher basic and diluted earnings per share from continuing operations.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/es/real-estate-management-and-development/bme-mvc/metrovacesa-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Metrovacesa.</a></p> <p>The earnings release comes after a strong run in the shares, with a 30-day share price return of 30.26% and a 38.89% year to date share price return. The 5-year total shareholder return of 285.18% points to momentum that has built over time.</p> <p>If Metrovacesa‚Äôs move has caught your eye, it could be a good moment to broaden your search and check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/global\" rel=\"noopener noreferrer\" target=\"_blank\">96 top founder-led companies</a> as potential next ideas.</p> <p>With net income at ‚Ç¨56.86 million, earnings per share at ‚Ç¨0.38 and the share price up 38.89% year to date, is Metrovacesa still undervalued, or is the market already pricing in future growth?</p> <h2>Most Popular Narrative: 0.8% Undervalued</h2> <p>The most followed valuation narrative puts Metrovacesa‚Äôs fair value at ‚Ç¨13.10, just above the ‚Ç¨13.00 last close, which keeps the focus firmly on the details behind that estimate.</p> <blockquote> <p><em>Metrovacesa's dedicated investment in delivering only AA energy efficiency buildings surpassing regulatory standards positions the company to capture premium pricing, secure cheaper green financing, and establish clear leadership as sustainability becomes the decisive factor in real estate demand, supporting higher margins and asset valuations.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/l4qmrxqy-urbanization-and-green-building-will-drive-lasting-value\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what is baked into that ‚Ç¨13.10 fair value? The narrative leans on rising margins, steadier cash generation and a richer earnings multiple. The exact mix of growth, profitability and discount rate assumptions might surprise you.</p> <p><strong>Result: Fair Value of ‚Ç¨13.10 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/l4qmrxqy-urbanization-and-green-building-will-drive-lasting-value\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also need to weigh risks, such as weaker housing demand in Spain or higher construction and compliance costs that could squeeze future margins and cash generation.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/es/real-estate-management-and-development/bme-mvc/metrovacesa-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Metrovacesa narrative.</a></p> <h2>Another View: Pricing Looks Full On Earnings</h2> <p>The fair value narrative suggests Metrovacesa is only 0.8% undervalued at ‚Ç¨13.10, close to the ‚Ç¨13.00 share price. But on earnings, the picture is less relaxed, with a P/E of 34.7x versus a fair ratio of 12.2x, the European real estate average of 13.5x and a 14.5x peer average.</p> <p>That gap means the market is already paying a high price for each euro of current earnings, so any disappointment or reset in expectations could matter more than usual. Does that premium match your own view of the company‚Äôs future, or does it make you more cautious about what is already priced in?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/es/real-estate-management-and-development/bme-mvc/metrovacesa-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/es/real-estate-management-and-development/bme-mvc/metrovacesa-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"BME:MVC P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/91490c3e-a80b-4ae8-9554-84421457f827/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>BME:MVC P/E Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>With the mixed signals on value and expectations, do you feel the market is being too cautious or too optimistic? Take a moment to review the full picture for yourself and weigh both sides of the story with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/es/real-estate-management-and-development/bme-mvc/metrovacesa-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this earnings story has sharpened your focus, do not stop here. Widening your watchlist now could be the edge you regret skipping later.</p> <ul> <li>Spot potential mispricings early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">225 high quality undervalued stocks</a> that pair solid fundamentals with more modest expectations.</li> <li>Strengthen your income stream by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/global\" rel=\"noopener noreferrer\" target=\"_blank\">447 dividend fortresses</a> that combine 5%+ yields with an emphasis on staying power.</li> <li>Protect your downside by checking <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/global\" rel=\"noopener noreferrer\" target=\"_blank\">329 resilient stocks with low risk scores</a> that screen for resilient balance sheets and lower overall risk scores.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:20:56",
            "link": "https://simplywall.st/stocks/es/real-estate-management-and-development/bme-mvc/metrovacesa-shares/news/metrovacesa-bmemvc-valuation-check-after-strong-full-year-pr",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.</li> <li>This combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast‚Äôs early commercial trajectory and cost profile.</li> <li>We‚Äôll now examine how Mesoblast‚Äôs new Ryoncil revenue guidance reframes its investment narrative built around cell therapy commercialization and pipeline expansion.</li> </ul><p>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Mesoblast Investment Narrative Recap</h2><p>To own Mesoblast today, you need to believe that Ryoncil can scale from a niche pediatric GvHD launch into a broader cell therapy franchise while the company manages ongoing losses and funding needs. The sharp step up in reported revenue and the new US$110 million to US$120 million Ryoncil guidance sharpen the focus on near term execution: can demand ramp fast enough to ease cash burn, and will trial and regulatory timelines hold without costly delays?</p> <p>The half year 2025 results are the most relevant recent announcement here, because they show early financial traction alongside continuing losses. Revenue of US$51.34 million and a reduced but still sizeable net loss of US$40.16 million underscore the tension between growing top line and the risk that R&amp;D and commercial spend remain high if label expansions in adult GvHD, inflammatory bowel disease or chronic low back pain take longer than expected to translate into meaningful sales.</p> <p>Yet against this improving revenue picture, the risk that slower Ryoncil uptake or trial delays could still force fresh capital raises is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Mesoblast (it's free!)</a></p><p>Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Mesoblast's forecasts yield a A$3.83 fair value</a>, a 71% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:MSB 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/600844ad-7b8f-4b60-be67-41aeee6634b3/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:MSB 1-Year Stock Price Chart</figcaption></figure> <p>The more optimistic analysts were already assuming revenue could reach about US$1.1 billion and earnings about US$585 million by 2028, so compared with the more cautious concerns about cash burn and trial risk, their narrative is far more bullish and you should recognize that views on Mesoblast can differ widely and may shift again after this new Ryoncil guidance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 17 other fair value estimates on Mesoblast</a> - why the stock might be a potential multi-bagger!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Mesoblast research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Mesoblast research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/au\" rel=\"noopener noreferrer\" target=\"_blank\">10 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:11:43",
            "link": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why ServiceTitan (TTAN) Is Up 10.5% After Morgan Stanley Names It A Sector Top Pick",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent weeks, ServiceTitan was highlighted by Wall Street analysts as one of the best beaten down technology names, with Morgan Stanley upgrading it to Overweight and naming it a sector top pick while institutional investors such as Artisan increased their holdings following earlier software weakness.</li> <li>These moves underscore growing institutional and analyst confidence in ServiceTitan‚Äôs vertical software model for trades and its potential to expand across additional end markets and product lines.</li> <li>We‚Äôll now examine how this renewed analyst and institutional confidence, especially Morgan Stanley‚Äôs sector top pick call, could influence ServiceTitan‚Äôs investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>ServiceTitan Investment Narrative Recap</h2><p>To own ServiceTitan, you have to believe its vertical software can keep becoming the core system of record for trades while its AI, payments and MAX initiatives deepen customer reliance on the platform. The recent analyst upgrade and institutional buying may support sentiment around the near term catalyst of broader MAX and AI Pro adoption, but they do not remove the key risk that these agentic, automated workflows could prove harder for customers to implement at scale.</p> <p>Among recent announcements, the expansion of ServiceTitan‚Äôs AP Automation and fintech suite, including Tap to Pay and integrated financing, ties in most closely with the current bull thesis around usage based payments and higher take rates. If these tools see sustained customer adoption, they could reinforce the catalysts tied to payments and workflow automation that analysts are watching, even as questions about implementation complexity and returns on AI investments remain in focus.</p> <p>Yet behind the renewed optimism, investors should also be aware that the long term bet on AI driven automation and the MAX program could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on ServiceTitan (it's free!)</a></p><p>ServiceTitan's narrative projects $1.5 billion revenue and $188.8 million earnings by 2028. This requires 18.4% yearly revenue growth and about a $486.9 million earnings increase from -$298.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how ServiceTitan's forecasts yield a $136.33 fair value</a>, a 85% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TTAN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/254bf5df-024c-4f4c-b03f-feca2d584ec2/chart/quote-price\" width=\"746\"/></a><figcaption>TTAN 1-Year Stock Price Chart</figcaption></figure> <p>Five fair value estimates from the Simply Wall St Community span roughly US$38 to US$136 per share, showing how differently holders view ServiceTitan‚Äôs potential. Against that wide spread, the core debate around whether AI driven automation and MAX can deliver clear, scalable customer ROI becomes a key lens for thinking about the company‚Äôs longer term performance and invites you to compare several alternative viewpoints.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on ServiceTitan</a> - why the stock might be worth 48% less than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your ServiceTitan research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Our free ServiceTitan research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ServiceTitan's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:11:43",
            "link": "https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan/news/why-servicetitan-ttan-is-up-105-after-morgan-stanley-names-i",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Should Rising Analyst Optimism Around Earnings Shift On Holding‚Äôs (ONON) Long‚ÄëTerm Growth Narrative?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent days, On Holding attracted heightened attention as UBS and Zacks reiterated very positive views ahead of the company‚Äôs now-past 3 March 2026 earnings release, citing strong consumer momentum, solid revenue growth and earlier earnings surprises. </li> <li>This cluster of upbeat analyst commentary has sharpened focus on how On‚Äôs recent operational performance may be reshaping expectations for its long-term growth profile and profitability. </li> <li>Now, we‚Äôll examine how this rising analyst optimism around operational strength and upcoming results could influence On Holding‚Äôs existing investment narrative. </li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>On Holding Investment Narrative Recap</h2><p>To own On Holding, you need to believe its premium brand, product innovation and DTC focus can justify a high valuation and support durable growth. The immediate catalyst is the 3 March 2026 Q4 2025 earnings release, which sits at the center of the recent analyst optimism. The biggest near term risk is that expectations for continued revenue and earnings momentum are now elevated, so any disappointment could magnify share price volatility.</p> <p>The most relevant recent announcement is On‚Äôs 10 February 2026 confirmation of its Q4 2025 earnings date. With analysts already highlighting prior earnings surprises and solid revenue growth, this specific release has become a focal point for testing the bullish thesis on margins, DTC progress and international scaling. How the company‚Äôs reported sales and profitability compare with these expectations may either reinforce, or start to question, the current enthusiasm embedded in the shares.</p> <p>Yet beneath the upbeat commentary, the risk that heavy reliance on premium pricing could eventually face pushback is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on On Holding (it's free!)</a></p><p>On Holding‚Äôs narrative projects CHF5.0 billion revenue and CHF561.2 million earnings by 2028. This requires 22.9% yearly revenue growth and an earnings increase of about CHF425 million from CHF135.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how On Holding's forecasts yield a $61.90 fair value</a>, a 30% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ONON 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/quote-price\" width=\"746\"/></a><figcaption>ONON 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were assuming revenue could climb toward CHF 5.5 billion and earnings to about CHF 725 million by 2028, which is far more upbeat than consensus and could be challenged if the recent focus on Asia Pacific expansion leaves results more exposed to regional slowdowns or shocks.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 16 other fair value estimates on On Holding</a> - why the stock might be worth just $45.33!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your On Holding research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Our free On Holding research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate On Holding's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 best rare earth metal stocks</a> of the very few that mine this essential strategic resource.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:11:43",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/should-rising-analyst-optimism-around-earnings-shift-on-hold",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SentinelOne Unveils Identity Platform As Market Weighs Losses And Valuation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>SentinelOne (NYSE:S) has launched a next generation identity security platform focused on protecting both human users and AI agent accounts.</li> <li>The new offering shifts from traditional authentication checks to continuous, behavior based validation and runtime authorization withdrawal.</li> <li>The move targets rising identity centric threats as enterprises adopt more automation and AI driven workflows.</li> </ul> <p>SentinelOne enters this launch with shares at $13.48 and a mixed recent track record, including a 10.8% decline over the past 30 days and a 33.7% decline over the past year. For investors following NYSE:S, the new platform reflects how the company is trying to position itself in identity security as attack surfaces evolve.</p> <p>For investors and customers, the key question is how much demand develops for identity protection that explicitly includes AI agents alongside human users. This release also indicates where SentinelOne is focusing its product roadmap, which may influence how its role within broader cybersecurity exposure in a portfolio is evaluated.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">SentinelOne</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on SentinelOne.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:S Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f2abf38f-6e34-40bd-a59e-9d368e694ec3/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:S Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 2 risks for SentinelOne. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At $13.48 versus an average analyst target of $20.71, the price sits about 35% below consensus expectations.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are described as trading 44.4% below an estimated fair value, which flags potential upside based on that model.</li> <li><strong>‚ùå Recent Momentum</strong>: The stock has a 30 day return of about 10.8% decline, so the market has been cautious recently.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold SentinelOne: head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of SentinelOne's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The new identity platform extends SentinelOne's reach into protecting both human and AI agent accounts, which could broaden its role in zero trust and automation heavy environments.</li> <li>üìä Keep an eye on customer adoption, any commentary on AI related deal wins, and whether revenue of US$955.65m starts to reflect traction from this product line.</li> <li>‚ö†Ô∏è The company is currently loss making with net income of a US$411.29m loss and is flagged as not forecast to reach profitability within 3 years, so funding and cash burn remain key watchpoints.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">complete SentinelOne analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">community page for SentinelOne</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:11:42",
            "link": "https://simplywall.st/stocks/us/software/nyse-s/sentinelone/news/sentinelone-unveils-identity-platform-as-market-weighs-losse",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "United Therapeutics Tresmi Launch And Xenotransplant Progress Shape Valuation Story",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>United Therapeutics (NasdaqGS:UTHR) has introduced Tresmi, a new soft mist inhaler platform aimed at reducing treatment side effects, including coughing.</li> <li>The company reported record annual revenue alongside this product launch.</li> <li>United Therapeutics also reported tangible progress in its organ manufacturing program focused on xenotransplantation.</li> </ul> <p>For investors watching United Therapeutics at a share price of $503.6, these updates add fresh detail to the story behind NasdaqGS:UTHR. The stock is up 4.8% over the past week and 55.6% over the past year, with a very large 3-year gain and a 214.1% return over 5 years. In that context, the combination of a new inhaler platform, record revenue, and organ manufacturing progress provides more detail on recent share price strength.</p> <p>Looking ahead, Tresmi may influence how the company positions its inhaled therapies, particularly if reduced coughing is associated with better patient adherence. Progress in xenotransplantation research may also inform how investors view the company‚Äôs long-term pipeline and potential new revenue streams. Together, these developments may be important for how the market values future opportunities at United Therapeutics.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">United Therapeutics</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NasdaqGS/UTHR\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on United Therapeutics.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:UTHR Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:UTHR Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 0 risks for United Therapeutics. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: At US$503.6 versus a US$565.08 consensus target, the price sits about 11% below analyst expectations, which indicates potential upside in the current analyst view.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Simply Wall St currently sees United Therapeutics trading about 68.1% below its estimated fair value.</li> <li><strong>‚úÖ Recent Momentum</strong>: The 30 day return of roughly 5.6% reflects positive short term momentum as the market absorbs the Tresmi launch and organ manufacturing update.</li> </ul> <p>The decision to buy, sell or hold United Therapeutics depends on your own analysis. For more detail, see Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest assessment of United Therapeutics's fair value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä Tresmi and progress in xenotransplantation add another layer to the story alongside record revenue and existing pulmonary hypertension therapies.</li> <li>üìä It may be useful to monitor adoption of the new inhaler, any reported impact on side effects, and updates on organ manufacturing milestones or regulatory steps.</li> <li>‚ö†Ô∏è Execution risk around commercial uptake of Tresmi and the scientific, regulatory and cost hurdles in xenotransplantation could influence how quickly these projects affect results.</li> </ul> <h3>Dig Deeper</h3> <p>For a fuller picture, including additional risks and potential rewards, see the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">complete United Therapeutics analysis</a>. You can also visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NasdaqGS/UTHR\" rel=\"noopener noreferrer\" target=\"_blank\">community page for United Therapeutics</a> to see how other investors view the latest developments and their impact on the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:06:47",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-tresmi-launch-and-xenotransplant-progres",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Earnings Beat And New Audit Voice Altering The Investment Case For Darling Ingredients (DAR)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Darling Ingredients recently reported quarterly revenues that came in well above analyst expectations, with management highlighting strong operational execution, EBITDA growth and improved gross margins despite industry headwinds.</li> <li>The company also disclosed a planned 2026 retirement of long-time lead director Gary Mize and the immediate addition of former Cargill executive Robert Aspell to the board and Audit Committee, potentially sharpening oversight around global agriculture exposure and risk management.</li> <li>Against this backdrop of earnings outperformance and fresh audit expertise from Robert Aspell, we‚Äôll assess how Darling Ingredients‚Äô investment narrative may evolve.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Darling Ingredients Investment Narrative Recap</h2><p>To own Darling Ingredients, you need to believe its mix of rendering, renewable fuels and specialty ingredients can translate volatile inputs and policy swings into steadier cash generation. The latest revenue beat and margin improvement support that thesis, but do not materially change the near term focus on renewable fuel policy clarity as the key catalyst, or on weak recent profitability and high leverage as central risks.</p> <p>The most relevant development for that near term story is the board change. Adding former Cargill executive Robert Aspell, with deep global agriculture and risk experience, to the Audit Committee could sharpen oversight around feedstock exposure, capital allocation and compliance just as Darling works through margin volatility and balance sheet constraints in its Fuel and Feed segments.</p> <p>Yet against the recent earnings volatility and tight interest coverage, one area investors should be especially aware of is the risk that prolonged regulatory uncertainty could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Darling Ingredients (it's free!)</a></p><p>Darling Ingredients' narrative projects $6.5 billion revenue and $673.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Darling Ingredients' forecasts yield a $47.46 fair value</a>, a 10% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"DAR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/ddd8b6e1-179a-4580-91d0-0fba71c1152c/chart/quote-price\" width=\"746\"/></a><figcaption>DAR 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts expect revenue near US$6.8 billion and earnings around US$891.1 million by 2028, whereas concerns about rising capex and regulatory dependence paint a much tougher picture, and this quarter‚Äôs earnings beat and governance changes could ultimately shift how you weigh those competing views.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Darling Ingredients</a> - why the stock might be worth 10% less than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Darling Ingredients research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Darling Ingredients research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Darling Ingredients' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:06:47",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients/news/is-earnings-beat-and-new-audit-voice-altering-the-investment",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Lithia Motors (LAD) Valuation After Recent Share Price Pullback",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Why Lithia Motors stock is drawing attention now</h2> <p>Lithia Motors (LAD) has been on many investors‚Äô radar after recent share performance, with the stock showing a negative move over the month and past 3 months, prompting closer scrutiny of its current valuation.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Lithia Motors.</a></p> <p>At a share price of $281.46, Lithia Motors has seen a 1 day share price return of 0.69%, set against a weaker 30 day share price return of 13.97% and a 1 year total shareholder return of 17.7%. Together, these figures point to fading momentum after earlier gains over three years.</p> <p>If this pullback has you thinking about where else capital could work harder, it might be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With Lithia trading at $281.46, an indicated 58.71% discount to one intrinsic value estimate and a 39.81% discount to the average analyst target of $393.50, you have to ask: is this a genuine opportunity, or is the market already factoring in future growth?</p> <h2>Most Popular Narrative: 28.7% Undervalued</h2> <p>On the most followed narrative, Lithia Motors' fair value of $394.57 sits well above the current $281.46 share price, which puts a lot of focus on what is driving that gap.</p> <blockquote> <p><em>Ongoing technology investments, especially the full rollout of Pinewood.AI, are expected to materially lower SG&amp;A through automation, unified workflows, and improved productivity, driving operating leverage that should improve net margins and efficiency ratios over the next several years.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>If you want to see what is really baked into that valuation, the core of this narrative is a specific mix of revenue growth, margin uplift, and future earnings multiples that are anything but conservative.</p> <p><strong>Result: Fair Value of $394.57 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also have to keep an eye on risks such as elevated acquisition costs or weaker organic store performance, which could challenge those margin and earnings assumptions.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Lithia Motors narrative.</a></p> <h2>Next Steps</h2> <p>With both risks and rewards on the table, what matters most is how you weigh them for your own portfolio. Take a closer look at the full picture and let the data guide your stance through <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Lithia has sparked new questions about where your money works hardest, do not stop here. Let the screener surface fresh angles you might be missing.</p> <ul> <li>Target potential value opportunities by scanning companies on our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a> and see which ones match your return expectations and risk comfort.</li> <li>Prioritise stability by reviewing companies highlighted in the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">80 resilient stocks with low risk scores</a>, so you can focus on businesses with lower overall risk scores.</li> <li>Hunt for lesser known prospects through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> and spot companies that may not yet be widely followed.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:06:46",
            "link": "https://simplywall.st/stocks/us/retail/nyse-lad/lithia-motors/news/assessing-lithia-motors-lad-valuation-after-recent-share-pri-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Iovance Biotherapeutics (IOVA) Attractive After Recent 33% Weekly Share Price Jump",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Iovance Biotherapeutics at around US$3.79 is a bargain or a value trap, you are not alone. This article will walk through what the current price could mean for you.</li> <li>The stock has recently moved sharply, with a 33% return over the last 7 days, 27.2% over the last 30 days, and 50.4% year to date, even though the 1 year, 3 year and 5 year returns remain negative.</li> <li>These swings have come as investors react to ongoing developments around Iovance Biotherapeutics and its pipeline, which can quickly change sentiment around early stage biotech names. Understanding what is already baked into the share price matters if you are trying to work out whether recent moves reflect lasting shifts in expectations or short term trading.</li> <li>On our valuation checks the company scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4 out of 6</a> for being undervalued. Next we will look at how different valuation approaches line up on Iovance Biotherapeutics, and then finish with a way to put those numbers into a fuller investment story.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Iovance Biotherapeutics's -27.9% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: Iovance Biotherapeutics Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes estimates of a company‚Äôs future cash flows and discounts them back to today to arrive at an estimate of what the business could be worth right now.</p> <p>For Iovance Biotherapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is a loss of about $343.7 million. Analysts provide forecasts out to 2030, with free cash flow projections moving from a loss of $146 million in 2026 and $13 million in 2027, to positive cash flows of $143 million in 2028, $231 million in 2029 and $313 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates further free cash flow estimates out to 2035 using its own growth assumptions.</p> <p>When all of those projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $23.63 per share. Compared with the recent share price around $3.79, this implies the stock is about 84.0% undervalued on this measure.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Iovance Biotherapeutics is undervalued by 84.0%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IOVA Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>IOVA Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Iovance Biotherapeutics.</a></p> <h2>Approach 2: Iovance Biotherapeutics Price vs Sales</h2> <p>For companies that are not yet profitable, the P/S ratio is often more useful than P/E because it compares what investors are paying to the revenue being generated, rather than to earnings that are still negative.</p> <p>In general, higher expected growth and lower perceived risk can support a higher P/S ratio. Slower growth or higher risk tends to justify a lower one. That is why it helps to look at Iovance Biotherapeutics in the context of both its industry and its own fundamentals.</p> <p>Iovance Biotherapeutics currently trades on a P/S of 5.93x. This sits below the Biotechs industry average of 12.58x and also below the peer average of 6.82x provided. Simply Wall St‚Äôs Fair Ratio for the company is 4.19x, which is an estimate of the P/S multiple that might be reasonable given factors such as earnings growth, profit margins, industry, market cap and specific risks. Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored to the company‚Äôs profile.</p> <p>Putting that together, Iovance Biotherapeutics‚Äô actual P/S of 5.93x is above the Fair Ratio of 4.19x, which points to the shares pricing in a richer multiple than this framework suggests.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA P/S Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/ps-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA P/S Ratio as at Feb 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Iovance Biotherapeutics Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about Iovance Biotherapeutics tied directly to numbers like future revenue, earnings, margins and a fair value estimate.</p> <p>On Simply Wall St‚Äôs Community page, millions of investors use Narratives as an accessible tool to connect a company‚Äôs story to a financial forecast and then to a fair value. This allows you to compare that fair value with the current share price to help decide if the stock looks attractive or stretched on your assumptions.</p> <p>Because Narratives update automatically when new information such as company announcements, earnings or analyst revisions appear, you are not locked into a static view. You can quickly see how fresh data shifts the fair value output linked to your story.</p> <p>For Iovance Biotherapeutics, one investor might build a cautious Narrative anchored around a US$1.00 fair value while another might build an optimistic Narrative around US$20.00. By setting out the revenue, earnings and P/E assumptions behind each, you can decide which version feels closer to your own view or adjust the inputs to create something in between.</p> <p>For Iovance Biotherapeutics, we will make it easy for you with previews of two leading Iovance Biotherapeutics Narratives:</p> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/13svd0s7-amtagvi-and-new-til-will-meet-aging-global-demand?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Iovance Biotherapeutics Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$17.00 per share</p> <p>Implied discount to this fair value versus the recent US$3.79 share price: about 78% below the narrative fair value</p> <p>Revenue growth assumption in this narrative: 56.96% a year</p> <ul> <li>Assumes Amtagvi adoption, broader patient access, and efficiency gains support higher revenue and a turnaround from losses to profit over the next few years.</li> <li>Builds in a higher profit margin and a future P/E of 75.10x, which is well above the current US Biotechs industry P/E referenced earlier in the article.</li> <li>Anchors on a Fair Value of US$17.00, based on bullish analyst assumptions for revenue of US$1.0b and earnings of US$126.3m by 2028, discounted back at about 7.11%.</li> </ul> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/jv6qnzu7-rising-interest-rates-and-dilution-will-stifle-til-progress?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Iovance Biotherapeutics Bear Case</strong></a></p> <p>Fair value in this bearish narrative: US$2.00 per share</p> <p>Implied premium to this fair value versus the recent US$3.79 share price: about 89% above the narrative fair value</p> <p>Revenue growth assumption in this narrative: 43.28% a year</p> <ul> <li>Assumes slower commercialization, high costs, complex distribution, and pressure from drug pricing scrutiny and interest rates, with continued execution risk.</li> <li>Uses a lower profit margin of 3.20% and a future P/E of 50.65x, while still baking in material revenue growth from Amtagvi and the pipeline.</li> <li>Arrives at a Fair Value of US$2.00 per share, reflecting a cautious view that the market may be pricing in more growth and profitability than these assumptions support.</li> </ul> <p>Together, these Narratives frame the recent US$3.79 share price between a bullish fair value of US$17.00 and a bearish fair value of US$2.00. Your job is to decide which story, or something in between, best fits your own expectations for Iovance Biotherapeutics.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Iovance Biotherapeutics? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGM/IOVA\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 04:06:46",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/is-iovance-biotherapeutics-iova-attractive-after-recent-33-w",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Sysmex (TSE:6869) Now Fairly Priced After A 45% One Year Share Price Slide?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Sysmex shares are now priced attractively or still have further to fall, this article walks through what the current share price might be implying about the company's value.</li> <li>The stock last closed at ¬•1,467, after a 9.6% move over the past 7 days, a modest 0.3% return over 30 days, and longer term returns of a 4.4% decline year to date, a 44.9% decline over 1 year, a 45.0% decline over 3 years, and a 58.1% decline over 5 years.</li> <li>Recent coverage around Sysmex has focused on its position in the healthcare sector and how investors are reassessing companies in this space, especially those with established products and global reach. This backdrop helps frame why the share price has shifted recently and why some investors are rechecking their assumptions about what a fair price looks like today.</li> <li>On our valuation checks, Sysmex currently scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">3 out of 6</a>, meaning it screens as undervalued on half of the metrics we track. Next, we will look at what different valuation methods say about that score, before finishing with a more complete way to think about value that ties all of these pieces together.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Sysmex's -44.9% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Sysmex Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes estimates of the cash a company may generate in future years and discounts those amounts back into today‚Äôs money to arrive at an estimated intrinsic value per share.</p> <p>For Sysmex, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in ¬•. The latest twelve month free cash flow is ¬•27,423.60 million. Analyst estimates and subsequent extrapolations point to projected free cash flow of ¬•50,425.75 million by the year ending March 2030, with a series of annual projections between now and 2035 that Simply Wall St has discounted back to today.</p> <p>When all of those projected cash flows are added and discounted, the model arrives at an estimated fair value of ¬•1,567.57 per share. Compared with the recent market price of ¬•1,467, the DCF output implies Sysmex trades at about a 6.4% discount to this estimate, which places it in the ‚Äúroughly in line‚Äù bucket rather than looking extremely cheap or expensive.</p> <p><strong>Result: ABOUT RIGHT</strong></p> <p>Sysmex is fairly valued according to our <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Discounted Cash Flow (DCF)</a>, but this can change at a moment's notice. Track the value in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://www.simplywall.st/watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_fairly_valued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted on when to act.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"6869 Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bfd7ddf-83f1-49f8-bedf-8070df38967e/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>6869 Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Sysmex.</a></p> <h3>Approach 2: Sysmex Price vs Earnings</h3> <p>P/E is a useful way to think about valuation for profitable companies because it directly links what you pay for each share to the earnings that support that share. When investors expect stronger growth or see lower risk, they are usually willing to accept a higher P/E, while slower growth or higher risk tends to justify a lower P/E.</p> <p>Sysmex currently trades on a P/E of 20.4x. That is close to the Medical Equipment industry average of 15.5x and very similar to the peer average of 20.5x, so on simple comparisons the stock looks roughly in line with similar names rather than clearly cheap or expensive.</p> <p>Simply Wall St‚Äôs Fair Ratio is a proprietary estimate of what P/E might make sense for Sysmex given its earnings growth profile, industry, profit margins, market cap and risk factors. This is more tailored than a straight peer or industry comparison because those benchmarks do not adjust for company specific strengths or weaknesses. For Sysmex, the Fair Ratio is 26.6x, which is higher than the current 20.4x P/E, suggesting the shares trade below this estimate of fair value.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/healthcare/tse-6869/sysmex-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:6869 P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bfd7ddf-83f1-49f8-bedf-8070df38967e/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>TSE:6869 P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 12 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Sysmex Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to attach your own story about Sysmex to the numbers behind its fair value, revenue, earnings and margins.</p> <p>A Narrative is your view of what the company is doing, where it might be heading and how that could show up in future financials, all pulled together into one clear forecast and an implied fair value per share.</p> <p>On Simply Wall St, Narratives live in the Community page, where millions of investors can create and share these story driven forecasts, then compare their Fair Value to the current share price to help them decide how Sysmex fits into their portfolio.</p> <p>Because Narratives are refreshed when new information arrives, such as earnings updates or news, your fair value view can shift automatically. You will often see very different takes on Sysmex. For example, one Narrative might assume a much higher fair value than today‚Äôs price, while another assumes a much lower one, reflecting different expectations for its future.</p> <p>Do you think there's more to the story for Sysmex? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/TSE/6869\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/healthcare/tse-6869/sysmex-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:6869 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bfd7ddf-83f1-49f8-bedf-8070df38967e/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>TSE:6869 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 04:01:27",
            "link": "https://simplywall.st/stocks/jp/healthcare/tse-6869/sysmex-shares/news/is-sysmex-tse6869-now-fairly-priced-after-a-45-one-year-shar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Excellon Resources (TSXV:EXN) Valuation After The New Mallay Mineral Resource Estimate",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Excellon Resources (TSXV:EXN) has put the Mallay silver lead zinc mine in Peru back in focus after releasing its first independent Mineral Resource Estimate, a key input for potential restart planning.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Excellon Resources.</a></p> <p>The new Mallay resource update lands after a very large 1 year total shareholder return of about 4x, supported by a 107.87% 90 day share price return. However, 5 year total shareholder return remains deeply negative, suggesting momentum has picked up more recently than over the long run.</p> <p>If this kind of mining news has your attention, it could be a good time to see what else is moving in precious metals. You can explore our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_silver\" href=\"https://simplywall.st/discover/investing-ideas/473743/top-silver-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">7 top silver producer stocks</a>.</p> <p>With the Mallay resource now on the table and the share price up sharply over the past year, the key question is whether Excellon is still trading at a discount or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 97.9% Undervalued</h2> <p>According to the most followed narrative, Excellon Resources‚Äô fair value sits at CA$31.80 per share versus a last close of CA$0.66. This implies a very large gap between price and narrative value.</p> <blockquote> <p><em>Excellon has strong hands backing it, Glencore and Eric Sprott for example, and Glencore has an agreement to take all lead-zinc into 2027. Glencore is also assisting with the re-start of the Mallay mine and were partners with the former operators.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/hea33f2u-update-for-excellon-resources\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>If you want to understand why this narrative assigns such a high fair value, you need to see how the projected mine restarts, production volumes and metals pricing all fit together. The entire story hinges on how those assumptions feed into long term cash flows and what kind of valuation multiple that supports.</p> <p><strong>Result: Fair Value of CA$31.80 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/hea33f2u-update-for-excellon-resources\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this hinges on ambitious assumptions, and any setback at Mallay or a weaker than expected metals price backdrop could quickly challenge such an optimistic fair value.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Excellon Resources narrative.</a></p> <h2>Next Steps</h2> <p>With such a wide range of views on value and risk, it makes sense to look at the numbers yourself and decide where you stand. If you want a balanced snapshot of both sides, take a moment to review the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 4 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this story has you thinking harder about where your money is working, do not stop here. The next idea you skip could be the one that matters.</p> <ul> <li>Target potential mispricings across the market by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a> built from detailed fundamental checks.</li> <li>Strengthen the defensive side of your portfolio by focusing on companies flagged in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/ca\" rel=\"noopener noreferrer\" target=\"_blank\">7 resilient stocks with low risk scores</a>, where business quality is central.</li> <li>Hunt for lesser known opportunities by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/ca\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 6 high quality undiscovered gems</a> that surface on our screener before they hit the mainstream.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Excellon Resources might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/ca/materials/tsxv-exn/excellon-resources-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 04:01:27",
            "link": "https://simplywall.st/stocks/ca/materials/tsxv-exn/excellon-resources-shares/news/a-look-at-excellon-resources-tsxvexn-valuation-after-the-new",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}